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Inflammatory conditions characterized by excessive peripheral immune responses are associated with diverse alterations in brain
function, and brain-derived neural pathways regulate peripheral inflammation. Important aspects of this bidirectional peripheral
immune–brain communication, including the impact of peripheral inflammation on brain region–specific cytokine responses, and
brain cholinergic signaling (which plays a role in controlling peripheral cytokine levels), remain unclear. To provide insight, we studied
gene expression of cytokines, immune cell markers and brain cholinergic system components in the cortex, cerebellum, brainstem,
hippocampus, hypothalamus, striatum and thalamus in mice after an intraperitoneal lipopolysaccharide injection. Endotoxemia was
accompanied by elevated serum levels of interleukin (IL)-1β, IL-6 and other cytokines and brain region–specific increases in Il1b (the
highest increase, relative to basal level, was in cortex; the lowest increase was in cerebellum) and Il6 (highest increase in cerebellum; lowest increase in striatum) mRNA expression. Gene expression of brain Gfap (astrocyte marker) was also differentially increased. However, Iba1 (microglia marker) mRNA expression was decreased in the cortex, hippocampus and other brain regions in
parallel with morphological changes, indicating microglia activation. Brain choline acetyltransferase (Chat ) mRNA expression was
decreased in the striatum, acetylcholinesterase (Ache) mRNA expression was decreased in the cortex and increased in the hippocampus, and M1 muscarinic acetylcholine receptor (Chrm1) mRNA expression was decreased in the cortex and the brainstem.
These results reveal a previously unrecognized regional specificity in brain immunoregulatory and cholinergic system gene expression in the context of peripheral inflammation and are of interest for designing future antiinflammatory approaches.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2014.00147

INTRODUCTION
Dysregulated peripheral immune responses and cytokine release mediate

pathogenesis in sepsis, type 2 diabetes,
rheumatoid arthritis, lupus and other inflammatory and autoimmune conditions
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(1–4). Peripherally released cytokines and
other inflammatory molecules have also
been associated with brain immune activation and altered brain neuronal function in these disorders (5–13). Peripheral
inflammation and elevated systemic cytokine levels have been proposed to contribute to brain inflammation and pathogenesis in Alzheimer’s disease (14,15),
Parkinson’s disease (16) and schizophrenia (17). Furthermore, the brain plays an
important role in controlling peripheral
cytokine levels and inflammation via
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Figure 1. Peripheral LPS administration increases serum cytokine and chemokine levels. Mice were injected with LPS (8 mg/kg, IP) or saline
(S) and euthanized 4 h later. Serum IL-6, IL-1β, CXCL1, IFN-γ, IL-12p70, IL-10 and TNF were analyzed by using a multiplex platform, as described in Materials and Methods. Data are shown as mean ± SEM (n = 15 mice per group); ****P < 0.0001.

neural reflex circuits (1,2,18). We and
others have shown that brain cholinergic
signaling is an important component in
this regulation during inflammatory
conditions (19–23). This bidirectional
peripheral immune–brain communication in inflammatory disorders is a topic
of significant interest with potential therapeutic implications (18,24–29). Therefore, providing insight into specific aspects of this communication is necessary
and important.
Peripheral endotoxin (lipopolysaccharide [LPS]) administration in mice has
been used previously in studying peripheral immune–brain interactions. However, the impact of peripheral inflammation on brain cytokine gene expression
within specific brain regions in mice has
not been thoroughly examined. The predominant immune cells in the central
nervous system are microglia and astrocytes; microglia activation and astrogliosis, resulting from immune challenge or

neuronal damage, are associated with interleukin (IL)-1β, IL-6 and other inflammatory molecule production (30,31). Microglia and astrocytes also are active
modulators of neuronal synaptic interaction and neuronal plasticity (32,33), and
changes in microglia and astrocyte functional state can alter neuronal homeostasis and brain function (33–35). While a
role for brain cholinergic signaling in the
neural regulation of peripheral cytokine
release during endotoxemia and other inflammatory conditions has been previously indicated (19–23), the intriguing
question of whether acute peripheral inflammation affects the cholinergic system
in various brain regions has not been adequately addressed.
Here we aimed at providing insight
into the impact of peripheral inflammation on brain cytokine and cholinergic
system constituent gene expression. We
studied mRNA expression of cytokines
(Il1b and Il6), immune cytokine-producing
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cell markers (Gfap and Iba1) and cholinergic system components (Chat, Ache and
Chrm1) in seven brain regions after peripheral endotoxin administration in
mice.
The results reveal a somewhat surprising brain region–specific profile of Il1b
and Il6 gene expression in parallel with
differential alterations in Gfap, Iba1, Chat,
Ache, and Chrm1 gene expression during
peripheral systemic inflammation, accompanied by high-serum IL1β, IL-6 and
other cytokine levels. These results highlight new aspects of a peripheral
immune–brain communication.
MATERIALS AND METHODS
Animals and LPS Treatment
Male Balb/c mice (5–6 months old,
Taconic) were used in the experiments.
Animals were housed under standard
conditions (room temperature 22°C with
a 12-h light-dark cycle) and had free ac-
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cess to standard chow and water. Animals were allowed to acclimate for at
least 20 d before experiments. All animal
experiments were performed in accordance with the Guide for the Care and Use
of Laboratory Animals (36) under protocols
approved by the Institutional Animal
Care and Use Committee of the Feinstein
Institute for Medical Research, North
Shore–LIJ Health System (Manhasset,
NY, USA).
Endotoxemia and Sample Preparation
Lethal inflammation in mice was induced by administering LPS (endotoxin,
Escherichia coli 0111:B4; Sigma-Aldrich,
St. Louis, MO, USA). LPS (in pyrogenfree saline) was sonicated for 30 min and
injected intraperitoneally (IP) in mice in
a dose of 8 mg/kg. Control mice were
injected with saline (IP). Mice injected
with LPS or saline (n = 15 per group)
were euthanized 4 h after injection by
carbon dioxide asphyxiation. Blood was
collected immediately after euthanasia
by cardiac puncture. Brains were isolated on ice and dissected through the
midsagittal plane. The left hemisphere
was transferred into 4% paraformaldehyde and subsequently processed for
hematoxylin and eosin (H&E) staining
and immunohistochemistry (see below
for details). The cerebral cortex, cerebellum, brainstem, hippocampus, hypothalamus, striatum and thalamus were dissected on ice by using a binocular
dissection microscope by a trained and
highly experienced neuroscientist according to a modified method previously described by Glowinski and
Iversen (37). Brain tissue was snap
frozen on dry ice and transferred to storage at –80°C.
Serum Cytokine Determination
To obtain serum samples, blood was
allowed to clot for 1.5 h and was centrifuged at 1,500g for 10 min. Supernatants (sera) were collected and kept at
–20°C before cytokine analyses. IL-6,
IL-1β, chemokine (C-X-C motif) ligand
(CXCL1), IL-12p70, interferon (IFN)-γ,
IL-10 and tumor necrosis factor (TNF)

Figure 2. Relative Il1b mRNA expression is differentially increased in various brain regions
after peripheral LPS administration. Mice were injected with LPS (8 mg/kg, IP) or saline and
euthanized 4 h later. Brain regions were isolated and processed for Il1b mRNA expression
analysis by qPCR, as described in Materials and Methods. Data are shown as mean ± SEM
and fold-change (n = 15 mice per group); ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05.
Because of limited RNA levels in the hippocampus, hypothalamus, striatum and thalamus,
three tissue samples (from the same region and treatment group) were combined before
RNA extraction; therefore, n = 5 was used for statistical analyses in these regions.

were determined by using the mouse
proinflammatory 7-Plex electrochemiluminescent kit (Meso Scale Discovery,
Gaithersburg, MD, USA), according to
the manufacturer’s recommendations.
RNA Isolation and Quantitative
Polymerase Chain Reaction
RNA from seven different brain regions
(cortex, cerebellum, brain stem, hippocampus, hypothalamus, striatum and
thalamus) was extracted using the
RNeasy Plus Universal Mini-Kit (Qiagen,
Germantown, MD, USA) after tissue homogenization with the Bullet Blender Homogenizer (Next Advance, Averill Park,
NY, USA) and the recommended bead
lysis kit. Because of limited RNA levels
found in the hippocampus, hypothala-

mus, striatum and thalamus, three tissue
samples were combined from the same
treatment groups before RNA extraction.
RNA was quantified and analyzed for purity by using the Nanodrop 1000 (Thermo
Scientific [Thermo Fisher Scientific Inc.,
Waltham, MA, USA]); 260:280 and 260:230
ratios were >2 and >1.8, respectively. Isolated RNA was frozen at –80°C until
quantitative polymerase chain reaction
(qPCR) assays. Specific primers for Il6,
Il1b, acetylcholinesterase (Ache), choline
acetyltransferase (Chat), glial fibrillary
acidic protein (Gfap), ionized calciumbinding adapter molecule1 (Iba1),
M1mAChR (Chrm1) and Hprt1 (internal
reference gene) were designed by using
the Roche Universal Probe Library Assay
Design Center with the assigned probes:
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fixed brain tissue were cut at 40 μm,
mounted on glass slides and air-dried.
The slides were stained and deparaffinized by using the Ventana symphony
staining system for H&E staining. Images
of brain sections were acquired at 20×
and 40× magnification with the use of a
Nikon Eclipse E400 microscope attached
to a Nikon Digital DS-Fi1 camera (Nikon
Inc., Melville, NY, USA) and Adobe Photoshop software (Adobe Systems Incorporated, San Jose, CA, USA). The morphology of the neurons in the cerebral
cortex, hippocampus and cerebellum and
Purkinje cells (in the cerebellum) were assessed and photographed (40× magnification) in at least three different highpower fields per brain region.

Figure 3. Relative Il6 mRNA expression is differentially increased in various brain regions
after peripheral LPS administration. Mice were injected with LPS (8 mg/kg, IP) or saline
and euthanized 4 h later. Brain regions were isolated and processed for Il6 mRNA expression analysis by qPCR, as described in Materials and Methods. Data are shown as mean
± SEM and fold-change (n = 15 mice per group); ****P < 0.0001, ***P < 0.0005, **P < 0.001,
*P < 0.005. Because of limited RNA levels in the hippocampus, hypothalamus, striatum
and thalamus, three tissue samples (from the same region and treatment group) were
combined before RNA extraction; therefore, n = 5 was used for statistical analysis in these
regions.

Il6, left, GCTACCAAACTGGATATAAT
CAGGA, right, CCAGGTAGCTATGGT
ACTCCAGAA, probe 6; Il1b, left, AGTTG
ACGGACCCCAAAAG, right, AGCTG
GATGCTCTCATCAGG, probe 38; Ache,
left, TTAGGGCTGGGATATAATACGAC,
right, GCCCCTAGTGGGAGGAAGT,
probe 52; Chat, left, AAGCTTCCACGCCAC
TTTC, right, AGAGCCTCCGACGAA
GTTG, probe 3; Iba1, left, GGATTTGCAG
GGAGGAAAAG, right, TGGGATCATC
GAGGAATTG, probe 3; Chrm1, left,
GGTCCCAGGAGACACTGC, right,
TCAGAGTAAGGGCATCACCA, probe 73;
and Hprt1, left, TCCTCCTCAGACCGC
TTTT, right, CCTGGTTCATCATCG
CTAATC, probe 95. RNA (100 ng/reaction)
was amplified using a Eurogentec reverse-

transcriptase qPCR master mix (AnaSpec,
EGT Corporate Headquarters, Fremont,
CA, USA) on a LightCycler 480
(F. Hoffmann-La Roche Ltd, Basel,
Switzerland), and the data were analyzed
by using the Roche LightCycler 480 SW
1.5 software. Relative changes in mRNA
expression were calculated as foldchanges (versus Hprt) by using the comparative Ct (ΔΔCt method) (38).
H&E Staining and Microscopic
Evaluation
Brains were immersed in 4% paraformaldehyde fixation fluid for at least 24 h.
Postfixed brain tissue was processed by
using standard techniques and was embedded in paraffin. Serial sections of
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Iba1 Staining and Microscopic
Evaluation
Fixed brains were cryoprotected in
30% sucrose, frozen and cut using cryostat. Coronal sections (30 μm) were collected in phosphate-buffered saline
(PBS). The immunohistochemistry was
carried out on free-floating sections. The
sections were incubated for 30 min in
0.3% H2O2-PBS to inactivate endogenous
peroxidase activity. The sections were
blocked and incubated with primary antibodies (anti-rabbit IBA1 1:100; Wako,
Cambridge, MA, USA) in PBS containing 0.3% (v/v) Triton-100, 2% (v/v) normal goat serum in PBS. The incubations
were performed overnight at 4°C with
gentle shaking. After several washes in
PBS, the sections were incubated with
biotinylated secondary antibodies
(1:200; Vector Laboratories, Burlingame,
CA, USA) for 1 h at room temperature.
The staining was visualized by using
the biotin-avidin-peroxidase method
(Elite Kit; Vector Laboratories) with
diaminobenzidine as the chromogen/
substrate and counterstained with
hematoxylin (Sk-4100 and HR-3401;
Vector Laboratories). Images of Iba1immunostained brain sections were acquired at 40× magnification with the
use of a Nikon Eclipse E400 microscope
attached to a Nikon Digital DS-Fi1 camera and Adobe Photoshop software.
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Microglial morphology in the cerebral
cortex and hippocampus were assessed
and photographed (40× magnification)
in at least three different high-power
fields per brain region.
Statistical Analysis
Data are expressed as mean ± standard error of the mean (SEM). Differences between experimental groups
were assessed by using a Student t test
(GraphPad Prism 6; GraphPad Software
Inc., La Jolla, CA, USA). Differences
with P < 0.05 were considered statistically significant.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Peripheral Inflammation Is Associated
with Brain Region–Specific Increases
in Proinflammatory Cytokine Gene
Expression
After the administration of LPS
(8 mg/kg, IP), increased serum IL-6,
IL-1β, CXCL1, IFN-γ, IL-12p70, IL-10
and TNF levels were determined at 4 h
compared with saline-injected control
mice (Figure 1). These elevated serum
cytokine levels indicated peripheral
systemic inflammatory responses,
which can ultimately lead to 80% mortality within 4 d, as demonstrated in a
parallel set of animals (Supplementary
Figure S1). IL-1β and IL-6 are major cytokine mediators of brain inflammatory
conditions (39). Peripheral LPS administration dramatically increased brain
Il1b and Il6 gene expression compared
with saline-injected controls, and these
(relative to basal level in saline-treated
mice) increases were region-specific
(Figures 2, 3). The highest upregulation
in Il1b mRNA expression was found in
the cortex (144-fold) and the lowest in
the cerebellum (29-fold) (Figure 2). The
highest Il6 mRNA expression elevation
was observed in the cerebellum (173fold) and the lowest in the striatum
(29-fold) (Figure 3). These levels of peripheral and brain inflammation were

Figure 4. Lethal inflammation is not associated with early brain neuronal cell death and
morphology alterations. Mice were injected with LPS (8 mg/kg, IP) or saline and euthanized 4 h later. Brain neuronal cell morphology was evaluated (using H&E-stained sections) in the cortex, cerebellum and hippocampus by assessing three visual fields per
brain region per mouse. Representative photomicrographs (40×) are shown of H&Estained sections of cortex-saline (A), cortex-LPS (B), cerebellum-saline (C), cerebellum-LPS
(D), hippocampus-saline (E) and hippocampus-LPS (F). Scale bar, 50 μm.

not associated with increased brain cell
damage, as evaluated by the number of
eosin-positive neurons identified in the
cortex, cerebellum and hippocampus
(Figure 4).
Peripheral Inflammation Alters
Microglia and Astrocyte Marker Gene
Expression
Microglia and astrocytes are the main
immune cell subtypes, associated with
innate immune responses and cytokine
production in the brain (30,31). qPCR
quantification of Gfap (astrocyte marker)
and Iba1 (microglia marker) mRNA expression have been used previously for
studying astrogliosis and microglia activation, respectively (13,40,41). Here, we
examined whether peripheral lethal inflammation affects astrocyte and/or mi-

croglia functional status by determining
Gfap and Iba1 mRNA expression in the
various brain regions. As shown in Figure 5, brain Gfap mRNA expression was
upregulated after peripheral LPS administration. Although the magnitude of
this upregulation was markedly lower
when compared with increases in Il1b
and Il6 gene expression, it was significant in the cortex (P < 0.0001), cerebellum (P < 0.0002), brainstem (P < 0.05),
hippocampus (P < 0.05) and thalamus
(P < 0.05). This upregulation was consistent with the proposed role of astrocytes
in the innate immune response within
the central nervous system and as cytokine producers (30). In contrast to the
elevated astrocyte marker gene expression, Iba1 gene expression was slightly
but significantly decreased in the cortex
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the striatum, where it was decreased
(P < 0.01).
No Chat mRNA was detected in the
cerebellum or hippocampus. Ache mRNA
expression was significantly decreased in
the cortex (P < 0.004) and increased in
the hippocampus (P < 0.01) (Figure 9). In
addition, lethal LPS-induced inflammation decreased Chrm1 (M1mAChR)
mRNA expression in the cortex (P <
0.002) and reduced gene expression to
undetectable levels in the brainstem (Figure 10). No Chrm1 mRNA expression
was detected in the cerebellum of control
or LPS-treated mice.

Figure 5. Gfap mRNA expression is increased in specific brain regions during lethal inflammation. Mice were injected with LPS (8 mg/kg, IP) or saline and euthanized 4 h later.
Brain regions were isolated and processed for Gfap mRNA expression analysis by qPCR,
as described in Materials and Methods. Data are shown as mean ± SEM (n = 15 mice per
group); ***P < 0.0001, **P < 0.0002, *P < 0.05. Because of limited RNA levels in the hippocampus, hypothalamus, striatum and thalamus, three tissue samples (from the same
region and treatment group) were combined before RNA extraction; therefore, n = 5
was used for statistical analysis in these regions.

(P < 0.0001), brainstem (P < 0.0001), hippocampus (P < 0.05), striatum (P < 0.05)
and thalamus (P < 0.05) (Figure 6) during peripheral inflammation. This somewhat unexpected observation prompted
us to additionally perform Iba1 protein
staining in two brain regions with significantly decreased Iba1 gene expression
(the cortex and hippocampus), to highlight the activation state of microglia. As
shown in Figure 7, Iba1 staining revealed a microglial morphological reorganization, as evidenced by increased
density of the Iba1-stained material,
thickening of ramifications and
processes and increased cytoplasm.
These alterations were predominantly
observed in the hippocampus of the
LPS-treated mice (Figure 7).

Peripheral Inflammation Results in
Specific Alterations in Cholinergic
System Component Gene Expression
Next, we examined the impact of
lethal inflammation on the expression of
major genes associated with the brain
cholinergic system. The gene expression
of choline acetyltransferase (ChAT) (the
enzyme implicated in acetylcholine
biosynthesis), acetylcholinesterase
(AChE) (the major enzyme in acetylcholine degradation) and the M1 subtype of muscarinic acetylcholine receptor (M1 mAChR) (an important receptor
involved in processing neurotransmission in the brain cholinergic synapse)
were studied. As shown in Figure 8,
lethal inflammation did not alter Chat
gene expression, with the exception of
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DISCUSSION
Herein, we show that peripheral administration of LPS, accompanied by
significant elevations of IL-1β and IL-6
and other inflammatory mediators in the
circulation, results in significant increases in Il1 and Il6 gene expression in
the mouse brain within 4 h and reveal a
previously unrecognized pattern of region specificity, characteristic for each of
these two cytokines. These increases
were associated with increased Gfap
mRNA expression and downregulation
of Iba1 mRNA expression in most of the
brain areas studied, along with specific
alterations in the gene expression of
main constituents of the brain cholinergic system.
Administration of a lethal dose of LPS,
a constituent of the outer membrane of
gram-negative bacteria, has been extensively used to model gram-negative
microorganism-induced septic shock, a
lethal condition in humans with no treatment available. Accordingly, evaluation
of the survival rate has been an important outcome in numerous studies using
the murine endotoxemia model. However, the effect of a lethal dose of LPS on
brain cytokine gene expression has not
been clearly elucidated. Moreover, we
and others have demonstrated that stimulation of brain cholinergic signaling by
M1 mAChR agonists or centrally acting
acetylcholinesterase inhibitors suppresses peripheral proinflammatory cytokine release and improves survival in
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Figure 6. Iba1 mRNA expression is decreased in specific brain regions during lethal inflammation. Mice were injected with LPS (8 mg/kg, IP) or saline and euthanized 4 h later. Brain
regions were isolated and processed for Iba1 mRNA expression analysis by qPCR, as described in Materials and Methods. Data are shown as mean ± SEM (n = 15 mice per
group); **P < 0.0001, *P < 0.05. Because of limited RNA levels in the hippocampus, hypothalamus, striatum and thalamus, three tissue samples (from the same region and treatment group) were combined before RNA extraction; therefore, n = 5 was used for statistical analysis in these regions.

endotoxemia and other inflammatory
conditions (20–23,42). Likewise, the impact of lethal LPS-induced peripheral inflammation on the expression of genes
involved in the brain cholinergic system
has not been examined.
Previous studies have demonstrated
significant upregulation in brain Il1b and
Il6 gene expression within 1–6 h after peripheral LPS administration. For instance,
induction of Il1b mRNA expression has
been reported in the rat brain as early as
1 h after LPS (2.5 mg/kg, intravenously
[IV]) administration, peaking at 6 h, and
microglia have been identified as the main
producers of IL-1β (43). In a nonlethal
model of endotoxemia, significant increases in Il1b and Il6 gene expression
were reported within 1–4.5 h after LPS

(5 mg/kg, IV) injection in rats (44). Likewise, a sublethal dose of LPS administered
systemically to rats has been shown to induce significantly increased hypothalamic
Il6 mRNA expression as early as 2 h after
LPS administration (45). On the basis of
these previous findings, we considered the
4-h time point after LPS administration as
an appropriate time for evaluating inflammatory gene expression in the brain of endotoxemic versus control mice.
Peripheral administration of LPS significantly increased both Il1b and Il6
mRNA expression in all brain regions
studied, with the highest magnitude in
the cortex and hippocampus for Il1b and
in the cerebellum and brainstem for Il6.
These increases were associated with upregulation in Gfap mRNA expression in

the cortex, hippocampus, cerebellum and
other brain regions. These observations
are consistent with the important role of
astrocytes in IL-1β and IL-6 production.
The correlation between upregulated cytokine and astrocyte marker mRNA expression are in accordance with data
characterizing brain inflammation in the
context of diet-induced obesity in mice.
Gfap mRNA expression has been shown
to be significantly elevated in hypothalamus of mice with diet-induced obesity simultaneously with increased expression
of mRNA encoding myeloid cell–specific
markers Cd68 and Emr1 (13). These
changes, indicating active gliosis, occur in
parallel with increased hypothalamic Il1b
and Il6 mRNA expression (13).
In contrast to increased Gfap, Iba1
mRNA expression was decreased in the
cortex, hippocampus and other brain regions 4 h after LPS administration. These
observations suggest a different effect of
peripheral inflammation, at this early
time point, on mRNA expression of markers of astrocyte and microglia activation.
Furthermore, the decrease in Iba1 gene expression in the cortex and hippocampus
was accompanied by increased Iba1 protein staining in these regions, indicating
morphological transformations pointing
toward microglia activation. These transformations in microglia morphology were
consistent with increased Il1b and Il6
mRNA expression in these two brain regions. Our observations suggest intriguing microglia morphofunctional fluctuations at the time point studied (4 h),
during which the decreased Iba1 mRNA
expression could be a stop signal preventing further microglia activation.
Microglial activation has been traditionally associated with morphological
transformations from a ramified “resting
state” to an amoeboid, macrophage-like
cell “activation state.” However, this concept has now evolved, and microglia
have been characterized at multiple morphofunctional stages, depending on the
condition studied, activating stimulus
and the time of study (32–34,46). We
should note that the morphological
changes observed in Iba1-positive mi-
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Figure 7. Lethal inflammation is associated with morphological alterations in microglia indicative of activation. Mice were injected with LPS (8 mg/kg, IP) or saline and euthanized
4 h later. Brain tissues were stained for Iba1 immunohistochemistry, as described in Materials and Methods. Iba1-stained microglia were evaluated in the cortex and hippocampus
by assessing three visual fields per brain region, per mouse. Microglia were faintly stained
with anti-Iba1 in the cortex and the hippocampus of saline-injected mice, while morphological changes of activated microglia, including cell body enlargement, shortening and
thickening of processes, were observed in these brain areas of LPS-injected mice. Representative photomicrographs (40×) of Iba1-stained sections are shown: cortex-saline (A),
cortex-LPS (B), hippocampus-saline (C) and hippocampus-LPS (D). Enlarged single cell images are shown on the upper right corners. Scale bar, 50 μm.

Figure 8. Lethal inflammation results in decreased Chat mRNA expression in the striatum.
Mice were injected with LPS (8 mg/kg, IP) or saline and euthanized 4 h later. Brain regions
were isolated and processed for Chat mRNA expression analysis by qPCR, as described in
Materials and Methods. Data are shown as mean ± SEM (n = 15 mice per group); *P <
0.01. Because of limited RNA levels in the hippocampus, hypothalamus, striatum and thalamus, three tissue samples (from the same region and treatment group) were combined
before RNA extraction; therefore, n = 5 was used for statistical analysis in these regions. No
Chat mRNA was detected in the cerebellum and hippocampus.
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croglia (increased processes density and
enlarged cytoplasm) do not entirely represent the notion of the amoeboid microglia activation state. Most likely, they
indicate a stage of microglia alteration
(33) that, in this case, occurs simultaneously with decreased Iba1 mRNA levels
and increased Il1b and Il6 mRNA expression. These microglia alterations at relatively early time points are in accordance
with previous studies demonstrating increased staining of microglia in the hippocampus and other brain regions as
early as 3 h after LPS (5 mg/kg, IV) injection in rats (47), or in the cortex and
hippocampus after LPS (5 mg/kg, IP) injection in mice (48). A recent study using
intraperitoneal administration of a sublethal dose of LPS revealed alterations in
microglial morphological plasticity as
early as 2 h after LPS administration
manifested by reductions in the length of
microglial processes in the hippocampus
(46).
Mechanisms underlying the impact of
LPS-induced peripheral inflammation on
the brain have been previously highlighted (48–51). Direct activation of immune responses in the brain by peripherally administered LPS does not seem to
play a primary role because of poor LPS
penetration across the blood–brain barrier (48). Instead, cytokines and other inflammatory molecules, released during
endotoxemia, have been shown to signal
the brain and trigger immune responses.
The functional anatomy of this cytokinemediated transfer of peripheral inflammation to the brain involves several
mechanisms: crossing the blood–brain
barrier by a saturable carrier-mediated
mechanism; binding receptors at the surface of the endothelium of brain capillaries resulting in the release of soluble mediators, such as prostaglandins and nitric
oxide; and acting via circumventricular
organs that lack blood–brain barrier function (28,51). Accordingly, in our study, alterations in gene expression of inflammatory molecules in the brain were detected
on the background of significantly increased circulatory IL-1β, IL-6 and other
cytokine levels, with a previously indi-
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cated mediating role in immune cell activation in the brain (49). The expression of
TLR4 and cytokine receptors on microglia
and astrocytes provide a triggering mechanism for the activation of NF-κB and
other intracellular signal transduction
molecular components attributed to IL-6,
IL-1β and other cytokine production.
The transmission of peripheral cytokine
signals to the brain can also occur through
vagus nerve sensory fibers, and the role of
this neural pathway has been shown to
depend on the magnitude of the immune
challenge (50,51). This neural signaling
constitutes the afferent arm of the inflammatory reflex, which controls peripheral
cytokine release and inflammation
through efferent vagus nerve signaling,
termed the cholinergic antiinflammatory
pathway (1,52–57). This efferent vagus
nerve–based antiinflammatory mechanism
can be modulated by brain cholinergic signaling. Centrally acting acetylcholinesterase inhibitors and M1 mAChR
agonists have been shown to suppress peripheral cytokine release, to improve survival in endotoxemia (20,21) and to have
antiinflammatory effects in other inflammatory conditions (22,23,42). Despite the
important role of brain cholinergic signaling in controlling peripheral inflammation, the intriguing question of whether
lethal systemic inflammatory responses affect the brain cholinergic system has not
been evaluated. Here we show that peripheral inflammation leads to brain region–specific alterations in the expression
of genes, encoding important molecules
linked to cholinergic signaling. These alterations occur in parallel with a lack of
increased brain neuronal damage in LPStreated mice, an observation consistent
with a previous study reporting no
necrotic tissue damage or other visible abnormalities in the brain after LPS
(5 mg/kg, IV) injection in rats (47). We detected no major changes in brain Chat
mRNA expression during peripheral inflammation, with the exception of a decrease in the striatum—an area with large
cholinergic neurons (intraneurones),
which do not project to other brain areas,
and in which ACh is locally released (58).

Figure 9. Lethal inflammation results in region-specific alterations in brain Ache mRNA expression. Mice were injected with LPS (8 mg/kg, IP) or saline and euthanized 4 h later.
Brain regions were isolated and processed for Ache mRNA expression analysis by qPCR,
as described in Materials and Methods. Data are shown as mean ± SEM (n = 15 mice per
group); ***P < 0.004, **P < 0.01. Because of limited RNA levels in the hippocampus, hypothalamus, striatum and thalamus, three tissue samples (from the same region and treatment group) were combined before RNA extraction; therefore, n = 5 was used for statistical analysis in these regions.

Apart from the striatum, brain cholinergic
neurons are predominantly localized in
basal forebrain cholinergic nuclei and in
the mesopontine/upper brainstem pedunculopontine and laterodorsal tegmental
nuclei in proximity or giving projections
to the cortex, hippocampus, hypothalamus and thalamus (58–60). Extremely low
Chat mRNA expression in projections to
cerebellum and hippocampus (61) could
explain the lack of measurable Chat gene
expression in these brain regions. We also
show here that Ache mRNA expression is
decreased in the cortex and increased in
the hippocampus. In addition to revealing
a differential early impact of peripheral inflammation on Ache gene expression, these
observations are interesting from the perspective of suggesting brain regions that

can be targeted by centrally acting AChE
inhibitors with previously indicated antiinflammatory function (21,22,42). In addition, our data show the downregulation of
Chrm1 (M1 mAChR) mRNA expression in
the cortex and a dramatic decline of Chrm1
mRNA in the brainstem. We have previously shown that central M1 mAChR agonist treatments suppress proinflammatory
cytokine release in the periphery (20,22).
Together, these observations suggest that
the antiinflammatory role of the brain M1
mAChR might, at least at the mRNA level,
be mitigated during inflammation. Interestingly, decreased Chrm1 gene expression
has been previously determined in cortex
of patients with schizophrenia (62–64), a
disease associated with central and peripheral inflammation with a proposed
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tions, which may lead to developing new
therapeutic approaches.
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Figure 10. Lethal inflammation results in brain region–specific decreases in Chrm1 mRNA
expression. Mice were injected with LPS (8 mg/kg, IP) or saline and euthanized 4 h later.
Brain regions were isolated and processed for Chrm1 mRNA expression analysis by qPCR,
as described in Materials and Methods. Data are shown as mean ± SEM (n = 15 mice per
group); ***P < 0.002. Because of limited RNA levels in the hippocampus, hypothalamus,
striatum and thalamus, three tissue samples (from the same region and treatment group)
were combined before RNA extraction; therefore, n = 5 was used for statistical analysis in
these regions. No Chrm1 mRNA was detected in the cerebellum of LPS-treated mice.

pathogenic role (17). The lack of measurable Chrm1 mRNA expression in the cerebellum is in line with the extremely low
(<5%) contribution of this subtype to the
total M1 mAChR number (65,66). The
brain regions studied here have specialized physiological functions and most of
them are involved in the central control of
the autonomic nervous system regulation,
including peripheral immune modulation
(67,68). Future investigation of the impact
of alterations in brain cholinergic and cytokine gene expression on specialized
brain functions, attributed to a specific region, would contribute to further assessment of the importance of these alterations
in inflammatory conditions.
CONCLUSION
These results reveal a previously unrecognized regional specificity of brain
Il1b and Il6 mRNA expression in acute
systemic inflammatory settings. This result is associated with differential increases in brain Gfap mRNA expression,
consistent with the role of astrocytes in
cytokine production.

In contrast, under these conditions,
brain Iba1 mRNA expression is differentially decreased in parallel with morphological changes, indicative of microglial
activation, thus highlighting an intriguing complexity of brain immunoregulatory events. In addition, our results show
that brain cholinergic signaling known to
play a role in the regulation of peripheral
inflammation can in turn be specifically
altered by a peripheral inflammatory insult. Inflammation mediates pathogenesis in a variety of human diseases, and
murine and human endotoxemia have
been widely used to investigate aspects
of adverse inflammatory effects. One of
these aspects is the impact of peripheral
inflammation on brain immunoregulatory and neuronal function, with particular relevance to sepsis and septic shock,
type 2 diabetes, rheumatoid arthritis and
brain neurodegenerative diseases in
which cholinergic signaling also is dysregulated. Therefore, our findings provide a platform for future studies of the
brain immunoregulatory and neuromodulatory systems in inflammatory condi-
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